僅用于工業(yè)應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Eculizumab （Anti-Complement C5） is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex （MAC）. Eculizumab has the potential for haemolysis research.